Michael Frederick Press, MD, PhD

Professor of Pathology

Harold E. Lee Chair in Breast Cancer Research

Director of Breast Cancer Analysis Lab

Image of Michael Frederick Press, MD, PhD
Is this your profile? Click to edit

Overview

Michael F. Press, M.D., Ph.D. is a professor in the Department of Pathology and co-leader of the Women’s Cancers Program. He received his M.D., Ph.D. and residency training at the University of Chicago. He was a member of the University of Chicago faculty for seven years before joining the faculty of the University of Southern California in 1988. Dr. Press is currently the director for the Breast Cancer International Research Group Central Laboratory, the coordinator of the Breast Cancer Program at USC Norris Cancer Center and holds the Harold E. Lee Chair in Cancer Research in the USC Norris Cancer Center. His research interests are molecular genetic alterations in breast and gynecologic cancers.

Research Funding

  • HER-2 NEU PROTO-ONCOGENE IN OVARIAN &ENDOMETRIAL CANCER
    NIH · R01CA050589 · Feb 1, 1991 – Jan 31, 1995 · Role: Principal Investigator
  • PATHOBIOLOGY OF BREAST CANCER AND HORMONE RECEPTORS
    NIH · R01CA048780 · Apr 1, 1988 – Jan 31, 2006 · Role: Principal Investigator

Publications

  • RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer. Geburtshilfe Frauenheilkd. 2024 Jan; 84(1):77-85.. View in PubMed
  • Discordance of HER2 Expression and/or Amplification on Repeat Testing. Mol Cancer Ther. 2023 08 01; 22(8):976-984.. View in PubMed
  • ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023 08; 34(8):645-659.. View in PubMed
  • Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors. Clin Cancer Res. 2023 06 01; 29(11):2131-2143.. View in PubMed
  • Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. J Clin Oncol. 2023 03 20; 41(9):1638-1645.. View in PubMed
  • Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). Breast Cancer Res. 2023 01 11; 25(1):2.. View in PubMed
  • A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix® PC1 System. Cancers (Basel). 2022 Oct 26; 14(21).. View in PubMed
  • A Systematic Review and Meta-Analysis of Smoking and Circulating Sex Hormone Levels Among Premenopausal Women. Nicotine Tob Res. 2022 10 26; 24(11):1705-1713.. View in PubMed
  • Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach. Hum Mol Genet. 2022 09 10; 31(18):3133-3143.. View in PubMed
  • Lifetime personal cigarette smoking and risk of young-onset breast cancer by subtype among non-Hispanic Black and White women in the Young Women’s Health History Study. Breast Cancer Res Treat. 2022 Oct; 195(3):353-366.. View in PubMed